ArticleDrug design, development and therapy2026
Median Effective Concentration of Ropivacaine for Ultrasound-Guided T
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with end-stage renal disease (ESRD) may exhibit altered pharmacokinetic and pharmacodynamic responses to local anesthetics. But the ropivacaine concentration-response profile for ultrasound-guided T Methods: In this prospective dose-finding study, patients aged 18-75 years with ESRD and ASA physical status II-III undergoing elective PDC received ultrasound-guided T Results: 27 patients completed the study. EC50 was 0.173% (95% CI: 0.100%-0.500%) by CIR-PAVA and 0.180% (95% CI: 0.109%-0.225%) by probit regression. The wider CIR-PAVA CI reflects the small sample size and limited precision. Median global QoR-40 score at 24 hours was 184.0. Five patients (18.5%) required rescue analgesia. No serious adverse events, local anesthetic systemic toxicity, pneumothorax, or neurological complications occurred. Conclusion: The EC50 of ropivacaine for TPVB in ESRD patients undergoing PDC was approximately 0.17%-0.18%, with favorable early recovery and acceptable safety. Given that EC50 reflects efficacy in only 50% of patients, EC90/EC95 studies are needed before definitive dosing recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.